Sunrest Lifescience Ltd

SUNREST NSE Healthcare Pharmaceuticals
₹61.65
+0.00%
Delayed · cached 15 min

Fair value analysis

SUNREST
Sunrest Lifescience Ltd
HealthcarePharmaceuticals
₹37.20
Close used for this calculation
₹93.15Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
72/100
Profitability21/25
Returns23/25
Balance Sheet6/25
Efficiency22/25
Growth20/25
Strong
Quality radar
72Prof.21/25Ret.23/25Eff.22/25B.Sht6/25Growth20/25

Consensus fair value

₹93.15
Below FV
▲ +150.4% against the close used
Model range ₹50.06 – ₹215.72
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹50.06Fair value₹93.15Bull₹215.72
FairClose
52-week traded range
52W low ₹30.0552W high ₹49.65

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Sunrest Lifescience Ltd closed at ₹37.20, 60.1% below the consensus fair value of ₹93.15 drawn from 9 valuation models.

Financial DNA score 72/100 — Strong. P/E of 7.9x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹95.08
+155.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹50.06
+34.6%
√(22.5 × EPS × BVPS)
EPS=4.79, BVPS=23.25
Graham Formula
₹215.72
+479.9%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=20%, FD=7%
P/E Fair Value
₹171.00
+359.7%
EPS × 35.7x (sector P/E)
EPS=4.79, Sector P/E=35.7x
Peter Lynch (PEG)
₹119.75
+221.9%
EPS × Growth% (PEG = 1 is fair)
EPS=4.79, g=25%
EV/EBITDA
₹204.04
+448.5%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=110M
Book Value (P/B)
₹95.32
+156.2%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=23.25, ROE=22.4%, g=6%, r=10%
Reverse DCF
₹37.20
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -5.9% | Historical: 25%
Margin of Safety
₹99.72
+168.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=132.97, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.